Abstract：
BACKGROUND: PRP is a rare entity of unknown etiopathogenesis. Lack of management guidelines makes it a challenge for clinicians.
OBJECTIVE: To add our experience to increase evidence about PRP.
METHODS: We performed a retrospective, descriptive and multicentric study of 65 patients with PRP, being the largest European case series of patients with PRP.
RESULTS: PRP was more frequent in male patients with an average age of 51 years, but erythrodermic forms presented in older patients (average age 61 years). Six (75%) paediatric patients and ten (60%) non-erythrodermic adults controlled their disease with topical corticosteroids. On the contrary, 26 (68%) erythrodermic patients required biologic therapy as last and effective therapy line requiring an average of 6.5 months to achieve complete response.
CONCLUSIONS: Our study showed a statistical difference in terms of outcome and response to treatment between children or patients with limited disease and patients who develop erythroderma.
OBJECTIVE: To add our experience to increase evidence about PRP.
METHODS: We performed a retrospective, descriptive and multicentric study of 65 patients with PRP, being the largest European case series of patients with PRP.
RESULTS: PRP was more frequent in male patients with an average age of 51 years, but erythrodermic forms presented in older patients (average age 61 years). Six (75%) paediatric patients and ten (60%) non-erythrodermic adults controlled their disease with topical corticosteroids. On the contrary, 26 (68%) erythrodermic patients required biologic therapy as last and effective therapy line requiring an average of 6.5 months to achieve complete response.
CONCLUSIONS: Our study showed a statistical difference in terms of outcome and response to treatment between children or patients with limited disease and patients who develop erythroderma.
摘要：
背景：PRP是一种未知病因的罕见实体。缺乏临床实践指南使临床医生的管理具有挑战性。
目的：将我们的经验添加到PRP的语料库证据中。
方法：这是一个回顾性研究，描述性,描述性65例PRP患者的多中心研究，欧洲有史以来最大的PRP患者病例系列报告.
结果：PRP在平均年龄为51岁的男性中更为普遍，然而，在老年患者中出现红皮病型(平均年龄，61年）。6名（75％）儿科患者和10名（60％）非红皮病患者成年人通过局部皮质类固醇控制了疾病。然而,26例（68％）红皮病患者需要生物疗法作为最后的有效疗法，平均6.5个月才能达到完全缓解。
结论：我们的研究表明，儿童在治疗结果和反应方面存在统计学差异，或患有局限性疾病的患者和患有红皮病的患者。
目的：将我们的经验添加到PRP的语料库证据中。
方法：这是一个回顾性研究，描述性,描述性65例PRP患者的多中心研究，欧洲有史以来最大的PRP患者病例系列报告.
结果：PRP在平均年龄为51岁的男性中更为普遍，然而，在老年患者中出现红皮病型(平均年龄，61年）。6名（75％）儿科患者和10名（60％）非红皮病患者成年人通过局部皮质类固醇控制了疾病。然而,26例（68％）红皮病患者需要生物疗法作为最后的有效疗法，平均6.5个月才能达到完全缓解。
结论：我们的研究表明，儿童在治疗结果和反应方面存在统计学差异，或患有局限性疾病的患者和患有红皮病的患者。
